{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:16:02Z","timestamp":1789992962110,"version":"4.0.1"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.gene.2026.150376","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:28:42Z","timestamp":1787930922000},"page":"150376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Role of estrogen receptor \u03b1 in the regulation of breast cancer progression: signaling pathways and therapeutic implications"],"prefix":"10.1016","volume":"1012","author":[{"given":"Betty Annie","family":"Samuel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvaraj","family":"Jubie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natarajan","family":"Jawahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PK. Krishnan","family":"Namboori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2026.150376_b0005","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer\u2014epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review","volume":"13","author":"\u0141ukasiewicz","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.gene.2026.150376_b0010","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/0008-5472.CAN-20-1171","article-title":"Estrogen receptor alpha mutations in breast cancer cells cause gene expression changes through constant activity and secondary effects","volume":"81","author":"Arnesen","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.gene.2026.150376_b0015","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3390\/ijms22020756","article-title":"A closer look at estrogen receptor mutations in breast cancer and their implications for estrogen and antiestrogen responses","volume":"22","author":"Clusan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.gene.2026.150376_b0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1210\/endrev\/bnac017","article-title":"Estrogen receptor signaling in the immune system","volume":"44","author":"Chakraborty","year":"2023","journal-title":"Endocrine Rev."},{"key":"10.1016\/j.gene.2026.150376_b0025","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s43018-024-00898-8","article-title":"ER\u03b1 dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER+ breast cancer","volume":"6","author":"Liang","year":"2025","journal-title":"Nat. Cancer."},{"key":"10.1016\/j.gene.2026.150376_b0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13046-020-01788-4","article-title":"The immunomodulatory effects of endocrine therapy in breast cancer","volume":"40","author":"Huang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.gene.2026.150376_b0035","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.3390\/jcm13061818","article-title":"Aromatase inhibitors and plasma lipid changes in postmenopausal women with breast cancer: a systematic review and meta-analysis","volume":"13","author":"B\u00e9rczi","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.gene.2026.150376_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/or.2025.1564642","article-title":"Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action","volume":"19","author":"Kim","year":"2025","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.gene.2026.150376_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115422","article-title":"Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: an overview","volume":"256","author":"Bhatia","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.gene.2026.150376_b0050","doi-asserted-by":"crossref","first-page":"21974","DOI":"10.1038\/s41598-023-49379-5","article-title":"THEM6 is a prognostic biomarker for breast cancer and is associated with immune infiltration","volume":"13","author":"Lu","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.gene.2026.150376_b0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ctrv.2016.11.001","article-title":"ESR1 mutations: moving towards guiding treatment decision-making in metastatic breast cancer patients","volume":"52","author":"Angus","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.gene.2026.150376_b0060","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0960-9776(19)31118-X","article-title":"Endocrine therapy resistance: new insights","volume":"48","author":"Lei","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.gene.2026.150376_b0065","doi-asserted-by":"crossref","first-page":"480","DOI":"10.37349\/etat.2022.00096","article-title":"Endocrine therapy resistance: what we know and future directions. Exploration of targeted anti-tumor therapy","author":"Musheyev","year":"2022","journal-title":"Explor Target Antitumor Ther."},{"key":"10.1016\/j.gene.2026.150376_b0070","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13058-025-02020-x","article-title":"ESR1 testing on FFPE samples from metastatic lesions in HR + \/HER2- breast cancer after progression on CDK4\/6 inhibitor therapy","volume":"27","author":"Venetis","year":"2025","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.gene.2026.150376_b0075","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3390\/cancers17101653","article-title":"Mechanisms and therapeutic strategies for endocrine resistance in breast cancer: a comprehensive review and meta-analysis","volume":"17","author":"Khan","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.gene.2026.150376_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102757","article-title":"The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens","volume":"299","author":"Vallet","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.gene.2026.150376_b0085","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.maturitas.2014.10.010","article-title":"Selective estrogen receptor modulators (SERMs): a review of clinical data","volume":"80","author":"Mirkin","year":"2015","journal-title":"Maturitas"},{"key":"10.1016\/j.gene.2026.150376_b0090","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41416-018-0369-2","article-title":"Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis","volume":"120","author":"Eggemann","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.gene.2026.150376_b0095","doi-asserted-by":"crossref","first-page":"e3410","DOI":"10.1210\/clinem\/dgaf038","article-title":"Altered expression of aromatase and estrogen receptors in adipose tissue from men with obesity or type 2 diabetes","volume":"110","author":"Ahmed","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.gene.2026.150376_b0100","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/GME.0000000000000426","article-title":"Aromatase inhibitors for prevention of breast cancer in postmenopausal women: a narrative review","volume":"22","author":"Behan","year":"2015","journal-title":"Menopause"},{"key":"10.1016\/j.gene.2026.150376_b0105","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.3747\/co.25.3735","article-title":"Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects","volume":"25","author":"Pistelli","year":"2018","journal-title":"Curr Onco."},{"key":"10.1016\/j.gene.2026.150376_b0110","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3390\/cancers16030552","article-title":"Therapies for the treatment of advanced\/metastatic estrogen receptor-positive breast cancer: current situation and future directions","volume":"16","author":"Rej","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.gene.2026.150376_b0115","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41416-021-01564-x","article-title":"ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges","volume":"126","author":"Herzog","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.gene.2026.150376_b0120","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-17-1229","article-title":"Discovery of selective estrogen receptor covalent antagonists for the treatment of ER\u03b1WT and ER\u03b1MUT breast cancer","volume":"8","author":"Puyang","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.gene.2026.150376_b0125","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acsmedchemlett.9b00397","article-title":"PROTAC-mediated degradation of estrogen receptor in the treatment of cancer","volume":"10","author":"Kargbo","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.gene.2026.150376_b0130","doi-asserted-by":"crossref","first-page":"20933","DOI":"10.1021\/acs.jmedchem.4c01401","article-title":"Discovery of ERD-12310A as an exceptionally potent and orally efficacious PROTAC degrader of estrogen receptor \u03b1 (ER\u03b1)","volume":"67","author":"Rej","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.gene.2026.150376_b0135","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41557-023-01379-8","article-title":"Proteolysis-targeting chimeras with reduced off-targets","volume":"16","author":"Nguyen","year":"2024","journal-title":"Nat. Chem."},{"key":"10.1016\/j.gene.2026.150376_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.628690","article-title":"Activation of PI3K\/AKT\/mTOR pathway causes drug resistance in breast cancer","volume":"12","author":"Dong","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.gene.2026.150376_b0145","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamaoncol.2018.0060","article-title":"Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: a clinical trial","volume":"4","author":"Royce","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.gene.2026.150376_b0150","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s12282-017-0812-x","article-title":"Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K\/Akt\/mTOR in estrogen receptor-positive, HER2-negative breast cancer","volume":"25","author":"Araki","year":"2018","journal-title":"Breast Cancer"},{"key":"10.1016\/j.gene.2026.150376_b0155","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/17425255.2019.1663169","article-title":"Molecular basis for class side effects associated with PI3K\/AKT\/mTOR pathway inhibitors","volume":"15","author":"Zhang","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.gene.2026.150376_b0160","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"O\u2019Leary","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.gene.2026.150376_b0165","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","article-title":"CDK4\/6 inhibition in cancer: beyond cell cycle arrest","volume":"28","author":"Goel","year":"2018","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.gene.2026.150376_b0170","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10549-019-05133-y","article-title":"Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials","volume":"174","author":"Petrelli","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.gene.2026.150376_b0175","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.21037\/apm-21-1096","article-title":"Side effects of CDK4\/6 inhibitors in the treatment of HR+\/HER2\u2212 advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Yang","year":"2021","journal-title":"Ann Palliat Med."},{"key":"10.1016\/j.gene.2026.150376_b0180","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12282-017-0818-4","article-title":"Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis","volume":"25","author":"Kassem","year":"2018","journal-title":"Breast Cancer"},{"key":"10.1016\/j.gene.2026.150376_b0185","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/1535-7163.MCT-23-0351","article-title":"Palazestrant (OP-1250), a complete estrogen receptor antagonist, inhibits wild-type and mutant ER-positive breast cancer models as monotherapy and in combination","volume":"23","author":"Parisian","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.gene.2026.150376_b0190","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41523-023-00523-4","article-title":"An emerging generation of endocrine therapies in breast cancer: a clinical perspective","volume":"9","author":"Patel","year":"2023","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.gene.2026.150376_b0195","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41589-025-01866-8","article-title":"Native top-down proteomics enables discovery in endocrine-resistant breast cancer","volume":"21","author":"Gomes","year":"2025","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.gene.2026.150376_b0200","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The genomic landscape of endocrine-resistant advanced breast cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.gene.2026.150376_b0205","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41467-023-35795-8","article-title":"Control of protein stability by post-translational modifications","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.gene.2026.150376_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2021.100129","article-title":"Decoding post-Translational modification crosstalk with proteomics","volume":"20","author":"Leutert","year":"2021","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.gene.2026.150376_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2022.101097","article-title":"Pathological implication of protein post-translational modifications in cancer","volume":"86","author":"Pan","year":"2022","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.gene.2026.150376_b0220","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1007\/s00018-021-03860-4","article-title":"Estrogen receptor-\u03b1 signaling in post-natal mammary development and breast cancers","volume":"78","author":"Rusidz\u00e9","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.gene.2026.150376_b0225","article-title":"The N-terminal activation function AF-1 domain of ER\u03b1 interacts directly with the C-terminal AF-2-holding ligand-binding domain to recruit the coactivator proteins","volume":"19","author":"Liu","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.gene.2026.150376_b0230","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/receptors3020010","article-title":"Estrogen signals through ER\u03b2 in breast cancer; what we have learned since the discovery of the receptor","volume":"3","author":"Nagandla","year":"2024","journal-title":"Receptors"},{"key":"10.1016\/j.gene.2026.150376_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2023.109316","article-title":"Regulation of mRNA translation by estrogen receptor in breast cancer","volume":"200","author":"Fard","year":"2023","journal-title":"Steroids"},{"key":"10.1016\/j.gene.2026.150376_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2024.106526","article-title":"Estrogen receptor beta expression and role in cancers","volume":"242","author":"Monteiro","year":"2024","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.gene.2026.150376_b0245","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3389\/fendo.2018.00781","article-title":"Estrogen signaling in ER\u03b1-negative breast cancer: ER\u03b2 and GPER","volume":"9","author":"Girgert","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.gene.2026.150376_b0250","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1002\/ctm2.516","article-title":"Estrogen receptor variant ER\u03b146 and insulin receptor drive in primary breast cancer cells growth effects and interleukin 11 induction prompting the motility of cancer\u2010associated fibroblasts","volume":"11","author":"Cirillo","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.gene.2026.150376_b0255","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3389\/fendo.2020.00506","article-title":"A role for estrogen receptor alpha36 in cancer progression","volume":"11","author":"Pagano","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.gene.2026.150376_b0260","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41523-022-00470-6","article-title":"ER\u03b1-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance","volume":"8","author":"Strillacci","year":"2022","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.gene.2026.150376_b0265","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41586-024-08400-1","article-title":"The sequence\u2013structure\u2013function relationship of intrinsic ER\u03b1 disorder","volume":"638","author":"Du","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.gene.2026.150376_b0270","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.gene.2026.150376_b0275","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqae111","article-title":"ESR1 fusions invoke breast cancer subtype-dependent growth and survival","volume":"165","author":"Yates","year":"2024","journal-title":"Endocrinology"},{"key":"10.1016\/j.gene.2026.150376_b0280","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1080\/15476286.2024.2413821","article-title":"Estrogen receptor alpha (ER\u03b1) regulates PARN-mediated nuclear deadenylation and gene expression in breast cancer cells","volume":"21","author":"Varriano","year":"2024","journal-title":"RNA Biol."},{"key":"10.1016\/j.gene.2026.150376_b0285","doi-asserted-by":"crossref","first-page":"15395","DOI":"10.1021\/acsnano.4c14943","article-title":"Zooming into gene activation: estrogen receptor \u03b1 dimerization and dna binding visualized by high-speed atomic force microscopy","volume":"19","author":"Nishide","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.gene.2026.150376_b0290","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.3390\/cancers15194689","article-title":"Estrogen receptor signaling in breast cancer","volume":"15","author":"Miziak","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.gene.2026.150376_b0295","doi-asserted-by":"crossref","first-page":"6834","DOI":"10.3390\/ijms24076834","article-title":"A basic review on estrogen receptor signaling pathways in breast cancer","volume":"24","author":"Clusan","year":"2023","journal-title":"IJMS"},{"key":"10.1016\/j.gene.2026.150376_b0300","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1250218","article-title":"AIB1\/SRC-3\/NCOA3 function in estrogen receptor alpha positive breast cancer","volume":"14","author":"Kiliti","year":"2023","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1016\/j.gene.2026.150376_b0305","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.867448","article-title":"Decoding the therapeutic implications of the ER\u03b1 stability and subcellular distribution in breast cancer","volume":"13","author":"Tecalco-Cruz","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1016\/j.gene.2026.150376_b0310","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.cell.2019.06.026","article-title":"Therapeutic ligands antagonize estrogen receptor function by impairing its mobility","volume":"178","author":"Guan","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.gene.2026.150376_b0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273164","article-title":"Novel estrogen-responsive genes (ERGs) for the evaluation of estrogenic activity. Weisz A, editor","volume":"17","author":"Nishi","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.gene.2026.150376_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111453","article-title":"Non-genomic signaling of steroid receptors in cancer","volume":"538","author":"Thiebaut","year":"2021","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.gene.2026.150376_b0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-023-00533-2","article-title":"Estrogen\/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive\/HER2-positive breast cancer","volume":"9","author":"Pegram","year":"2023","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.gene.2026.150376_b0330","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3389\/fendo.2019.00708","article-title":"Non-canonical estrogen signaling in endocrine resistance","volume":"10","author":"Ranganathan","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.gene.2026.150376_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116393","article-title":"Dual-target inhibitors based on ER\u03b1: Novel therapeutic approaches for endocrine resistant breast cancer","volume":"270","author":"Xiong","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.gene.2026.150376_b0340","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1467033","article-title":"Endocrine treatment mechanisms in triple-positive breast cancer: from targeted therapies to advances in precision medicine","volume":"14","author":"Yang","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.gene.2026.150376_b0345","doi-asserted-by":"crossref","first-page":"e3998","DOI":"10.1002\/cbf.3998","article-title":"The PI3K\/AKT\/mTOR signaling pathway in breast cancer: review of clinical trials and latest advances","volume":"42","author":"Khorasani","year":"2024","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.gene.2026.150376_b0350","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clbc.2019.06.005","article-title":"A phase II open label study of everolimus in combination with endocrine therapy in resistant hormone receptor-positive HER2-negative advanced breast cancer","volume":"20","author":"Yardley","year":"2020","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.gene.2026.150376_b0355","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12672-024-01027-8","article-title":"BOLERO-5: a phase II study of everolimus and exemestane combination in chinese post-menopausal women with ER\u2009+\u2009\/HER2- advanced breast cancer","volume":"15","author":"Shao","year":"2024","journal-title":"Discov Onc."},{"key":"10.1016\/j.gene.2026.150376_b0360","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/s41388-022-02585-3","article-title":"Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program","volume":"42","author":"Bello Roufai","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.gene.2026.150376_b0365","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2026.150376_b0370","unstructured":"U.S. Food and Drug Administration. FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer. 10 October 2024. url: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive. Accessed on 17 Aug 2026."},{"key":"10.1016\/j.gene.2026.150376_b0375","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jsbmb.2017.08.013","article-title":"Hypoxia induced phosphorylation of estrogen receptor at serine 118 in the absence of ligand","volume":"174","author":"Park","year":"2017","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.gene.2026.150376_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113198","article-title":"Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4\/6 inhibitors in breast cancer","volume":"42","author":"Kim","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.gene.2026.150376_b0385","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.molcel.2019.03.020","article-title":"Cyclin D-Cdk4,6 drives cell-cycle progression via the retinoblastoma protein\u2019s c-terminal helix","volume":"74","author":"Topacio","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.gene.2026.150376_b0390","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.breast.2018.10.001","article-title":"Targeting CDK4\/6 pathways and beyond in breast cancer","volume":"43","author":"Ribnikar","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.gene.2026.150376_b0395","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.3390\/cancers12092480","article-title":"CDK4\/6 inhibitors in hormone receptor-positive metastatic breast cancer: current practice and knowledge","volume":"12","author":"de Melo","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.gene.2026.150376_b0400","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13058-022-01510-6","article-title":"Cellular mechanisms underlying response and resistance to CDK4\/6 inhibitors in the treatment of hormone receptor-positive breast cancer","volume":"24","author":"Watt","year":"2022","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.gene.2026.150376_b0405","doi-asserted-by":"crossref","first-page":"189","DOI":"10.62347\/HGNI4903","article-title":"Strategy of combining CDK4\/6 inhibitors with other therapies and mechanisms of resistance","volume":"17","author":"Xue","year":"2024","journal-title":"Int. J. Clin. Exp. Path."},{"key":"10.1016\/j.gene.2026.150376_b0410","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/2159-8290.CD-23-0954","article-title":"INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors","volume":"14","author":"Dietrich","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.gene.2026.150376_b0415","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1038\/s41591-024-03060-0","article-title":"Inhibition of lysine acetyltransferase KAT6 in ER+HER2\u2212 metastatic breast cancer","volume":"30","author":"Mukohara","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.gene.2026.150376_b0420","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/febs.17270","article-title":"Estrogen receptors and extracellular matrix: the critical interplay in cancer development and progression","volume":"292","author":"Mangani","year":"2025","journal-title":"FEBS J."},{"key":"10.1016\/j.gene.2026.150376_b0425","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/cancers14040909","article-title":"The impact of estrogens and their receptors on immunity and inflammation during infection","volume":"14","author":"Harding","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.gene.2026.150376_b0430","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000040845","article-title":"Lymphocyte infiltration in breast cancer: a promising prognostic indicator","volume":"103","author":"Obeagu","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.gene.2026.150376_b0435","doi-asserted-by":"crossref","DOI":"10.1172\/JCI155476","article-title":"The role of estrogen receptor signaling in suppressing the immune response to cancer","volume":"131","author":"Rae","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.gene.2026.150376_b0440","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","article-title":"Cancer associated fibroblasts in cancer development and therapy","volume":"18","author":"Jia","year":"2025","journal-title":"J. Hemat Onco."},{"key":"10.1016\/j.gene.2026.150376_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.preme.2024.100006","article-title":"Intratumor heterogeneity in breast cancer: tracing its origins and translating findings into clinical practice","volume":"1","author":"Gu","year":"2024","journal-title":"Precis Med. Eng."},{"key":"10.1016\/j.gene.2026.150376_b0450","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gene.2026.150376_b0455","doi-asserted-by":"crossref","first-page":"552","DOI":"10.7150\/ijbs.76187","article-title":"Targeting Breast Cancer Stem Cells","volume":"19","author":"Zhang","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.gene.2026.150376_b0460","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/mc.23277","article-title":"Breast cancer stem cells: a review of their characteristics and the agents that affect them","volume":"60","author":"Shan","year":"2021","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.gene.2026.150376_b0465","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.7150\/ijbs.27360","article-title":"Huaier polysaccharide inhibits the stem-like characteristics of ER\u03b1-36high triple negative breast cancer cells via inactivation of the ER\u03b1-36 signaling pathway","volume":"15","author":"Hu","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.gene.2026.150376_b0470","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13287-021-02321-w","article-title":"Signaling pathways governing breast cancer stem cells behavior","volume":"12","author":"Song","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.gene.2026.150376_b0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.12.012","article-title":"Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment","volume":"186","author":"Patel","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.gene.2026.150376_b0480","doi-asserted-by":"crossref","first-page":"e13098","DOI":"10.1200\/JCO.2024.42.16_suppl.e13098","article-title":"Switching from nonsteroidal aromatase inhibitors to exemestane and its impact on menopausal symptoms","volume":"42","author":"Blanter","year":"2024","journal-title":"J. Clin. Onco."},{"key":"10.1016\/j.gene.2026.150376_b0485","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/s41467-017-01864-y","article-title":"Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance","volume":"8","author":"Martin","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.gene.2026.150376_b0490","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41523-023-00601-7","article-title":"ER\u03b1\/PR crosstalk is altered in the context of the ER\u03b1 Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation","volume":"9","author":"Huggins","year":"2023","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.gene.2026.150376_b0495","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41416-020-01174-z","article-title":"RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer","volume":"124","author":"Dustin","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.gene.2026.150376_b0500","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.annonc.2023.09.3104","article-title":"Lasofoxifene versus fulvestrant for ER+\/HER2\u2212 metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial","volume":"34","author":"Goetz","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gene.2026.150376_b0505","doi-asserted-by":"crossref","first-page":"600","DOI":"10.18632\/oncotarget.28225","article-title":"A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis","volume":"13","author":"Asghari","year":"2022","journal-title":"Oncotarget"},{"key":"10.1016\/j.gene.2026.150376_b0510","first-page":"38","article-title":"ESR1 alterations and metastasis in estrogen receptor positive breast cancer","volume":"5","author":"Lei","year":"2019","journal-title":"J. Cancer Metastasis Treat."},{"key":"10.1016\/j.gene.2026.150376_b0515","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.2147\/CMAR.S137772","article-title":"Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence","volume":"10","author":"Rocca","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.gene.2026.150376_b0520","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1148792","article-title":"CDK4\/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective","volume":"11","author":"Zhou","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.gene.2026.150376_b0525","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s11658-022-00344-6","article-title":"The role of epigenetic modifications in drug resistance and treatment of breast cancer","volume":"27","author":"Karami Fath","year":"2022","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.gene.2026.150376_b0530","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant versus standard endocrine therapy for estrogen receptor-positive, HER2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gene.2026.150376_b0535","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","article-title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with ER-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.gene.2026.150376_b0540","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.01500","article-title":"Giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer: results from the randomized phase II acelERA trial","author":"Mart\u00edn","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gene.2026.150376_b0545","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2026.150376_b0550","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging esr1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"New Eng J Med."},{"key":"10.1016\/j.gene.2026.150376_b0555","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS1119","article-title":"evERA Breast Cancer (BC): phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2\u2013 LA\/mBC)","volume":"41","author":"Mayer","year":"2023","journal-title":"J. Clinical Oncol."},{"key":"10.1016\/j.gene.2026.150376_b0560","doi-asserted-by":"crossref","unstructured":"Roche. Giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer (lidERA BC). 18 November 2025. url: https:\/\/www.roche.com\/media\/releases\/med-cor-2025-11-18. Accessed on 17 Aug 2026.","DOI":"10.4000\/145n5"},{"key":"10.1016\/j.gene.2026.150376_b0565","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2026.150376_b0570","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"MONARCH 3: final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR-positive, HER2-negative advanced breast cancer","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gene.2026.150376_b0575","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2026.150376_b0580","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2026.150376_b0585","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.gene.2026.150376_b0590","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.canlet.2021.05.030","article-title":"Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer","volume":"517","author":"Dimitrakopoulos","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.gene.2026.150376_b0595","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10555-022-10066-y","article-title":"The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options","volume":"41","author":"Wang","year":"2022","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.gene.2026.150376_b0600","doi-asserted-by":"crossref","first-page":"57","DOI":"10.15212\/AMM-2024-0006","article-title":"New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives","volume":"3","author":"Min","year":"2024","journal-title":"Acta Materia Medica."},{"key":"10.1016\/j.gene.2026.150376_b0605","unstructured":"West German Study Group. Adj. Dynamic Marker - Adjusted Personalized Therapy Comparing Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy in (Clinical or Genomic) High Risk, HR+/HER2- EBC [Internet]. clinicaltrials.gov; 2025 Apr. Report No.: NCT04565054. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04565054. Accessed 16 Aug 2026."},{"key":"10.1016\/j.gene.2026.150376_b0615","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.toxlet.2022.03.003","article-title":"Cadmium and breast cancer \u2013 current state and research gaps in the underlying mechanisms","volume":"361","author":"Tarhonska","year":"2022","journal-title":"Toxicol. Lett."}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111926003860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111926003860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:48:07Z","timestamp":1789991287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111926003860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":122,"alternative-id":["S0378111926003860"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2026.150376","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of estrogen receptor \u03b1 in the regulation of breast cancer progression: signaling pathways and therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2026.150376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"150376"}}